
Recurrent pathogenic mutations in IDH1 and IDH2 at the conserved amino acid sites IDH1-R132, IDH2-R140 and IDH2-R172 occur in ~20% of patients with acute myeloid leukemia (AML).1 A recent analysis of AML patients at our institution identified IDH1/2 mutations in 20% (n=167) of 826 AML patients, with IDH1/2 mutations occurring most frequently in the setting of diploid karyotype or other intermediate-risk cytogenetics, particularly trisomy 8 (77 vs 53%, P<0.0005). AML patients with IDH1/2 mutations were overall less likely to have a diagnosis of therapy-related AML (8 vs 17%, P=0.003).2
Adult, Aged, 80 and over, Male, Adolescent, Middle Aged, Prognosis, Article, Isocitrate Dehydrogenase, Survival Rate, Young Adult, Myelodysplastic Syndromes, Mutation, Biomarkers, Tumor, Disease Progression, Humans, Female, Aged, Follow-Up Studies, Neoplasm Staging
Adult, Aged, 80 and over, Male, Adolescent, Middle Aged, Prognosis, Article, Isocitrate Dehydrogenase, Survival Rate, Young Adult, Myelodysplastic Syndromes, Mutation, Biomarkers, Tumor, Disease Progression, Humans, Female, Aged, Follow-Up Studies, Neoplasm Staging
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 103 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 1% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
